CD38 and plasma cell myeloma: We suggest that EPOCH combined with other less cytotoxic myeloma drugs, such as anti-CD38 antibodies or proteasome inhibitors, is a possible option for anaplastic myeloma, and perhaps also for other rapid growing variants of multiple myeloma, e.g., plasma cell leukaemia.